Intech Investment Management LLC Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Intech Investment Management LLC raised its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 80.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 97,793 shares of the biotechnology company’s stock after buying an additional 43,556 shares during the quarter. Intech Investment Management LLC’s holdings in BioCryst Pharmaceuticals were worth $735,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Fisher Asset Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in BioCryst Pharmaceuticals by 472.0% during the third quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock worth $3,776,000 after purchasing an additional 409,938 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after buying an additional 375,890 shares during the period. Cinctive Capital Management LP acquired a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at $2,082,000. Finally, Two Sigma Advisers LP raised its holdings in shares of BioCryst Pharmaceuticals by 13.6% in the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock valued at $16,576,000 after buying an additional 261,500 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 3.8 %

Shares of NASDAQ:BCRX opened at $7.98 on Monday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $9.50. The company’s 50 day moving average is $8.12 and its two-hundred day moving average is $7.82. The company has a market cap of $1.67 billion, a PE ratio of -13.08 and a beta of 1.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. BioCryst Pharmaceuticals’s revenue was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.28 earnings per share. As a group, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price for the company. JMP Securities restated a “market outperform” rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Finally, Evercore ISI increased their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.